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Acute myeloid leukemia (AML) with normal cytogenetics characterizes 40-50% of all 
acute leukemia cases [10].  Previous studies have shown that the Fms-like tyrosine 
kinase-3 internal tandem duplication (FLT3 ITD) mutation is found in ~30% of patients 
with AML. Another mutation, known as the partial tandem duplication of the Mixed 
Lineage Leukemia gene (MLL PTD) is found in ~4-7% of AML patients with no other 
chromosomal disruptions. In a subgroup of patients harboring the MLL PTD, co-presence 
of the FLT3 ITD has also been found.  Previously, we have generated and characterized 
the Mll PTD mouse model, and found that these mice live an essentially disease free life 
span with no signs of acute leukemia. Therefore, we wanted to determine whether the 
introduction of a second mutation such as the FLT3 ITD could cooperate with the Mll 
PTD to generate leukemia in a mouse model in order to better understand the 
pathogenesis of this disease. Indeed we found that the combination of MLL PTD and 
FLT3/ITD induces leukemia in our mouse model between 35-65 weeks of age in 100% of 
the mice analyzed thus far. Understanding how the FLT3 cooperates with the Mll PTD in 
leukemic transformation will,hopefully identify novel pathways that could be used to 
identify new strategies to selectively target these leukemia cells in AML patients. 
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The Mixed Lineage Leukemia (MLL) gene
Recurring chromosomal translocations are characteristic of human acute leukemias 
and the reproduction of translocations using mouse models are being studied to generate 
better understanding of leukemogenesis and new therapeutic approaches.  The Mixed 
Lineage Leukemia (MLL) gene, the human homolog of Drosophila Trithorax gene is 
located at 11q23 in the human genome.  MLL is located in a region of the human genome 
which is frequently rearranged in leukemia [17].  Studies suggest that normal MLL is
required for hematopoietic stem cell (HSC) development or the differentiation of the 
multipotenet HSC to lineage restricted hematopoietic progenitor cells (HPC) [3].   
Translocations found in acute leukemia involving 11q23 and result from the fusion of MLL 
with more than 40 possible different non-homologous partner genes.  In each case, the 
MLL protein retains its AT hook and methyltransferase domain at N-terminal end while 
losing the SET domain in its C-terminal portion.  
Although most of these gene rearrangements involving MLL result in chromosomal 
translocations, MLL itself was also found to be rearranged in 4-7% (of 956 cases) of 
patients with acute myeloid leukemia (AML) and normal cytogenetics [1, 11, 15]. This 
rearrangement consists of a partial tandem duplication of the N-terminus of MLL, in which 
a defined segment of the N-terminus is duplicated and inserted in tandem with an otherwise
full length MLL (Fig. 1).                                                   
3To create a mouse model of the Mll PTD exons 5-11 or 5-12 (formerly designated exons 2-
6 & 2-8) were inserted into intron 4 of the endogenous Mll gene.
Understanding the underlying molecular mechanisms involving Mll PTD-mediated 
leukemogenesis is especially important in patients harboring the MLL PTD, which 
consistently have shorter disease-free survival rates [15].  It is our hope that by generating 
the mouse model of the Mll PTD, we will begin to understand how the Mll PTD actually 
contributes to the leukemic phenotype and can then generated more appropriate treatments 
for this subgroup of patients. 
The FMS-Like Tyrosine kinase 3 (FLT3) gene.
Another gene aberration that appears frequently in acute leukemia involves
mutations of the FMS-like tyrosine kinase 3 (FLT3) gene.  FLT3 encodes a class III 
receptor tyrosine kinase [12] and is important for normal hematopoiesis [5, 16].  The FLT3 
gene is structurally related to c-kit (KIT), c-fms (FMS), and platelet derived growth factor
(PDGF) receptors, which are members of the class III receptor tyrosine kinase [12]. Normal 
FLT3 activates upon the binding of FLT3 ligand to the FLT3 receptor, which induces 
intracellular signaling pathways essential to regulation of cell proliferation, apoptosis,
maturation of myeloid and lymphoid progenitor cells, dendritic cells, and natural killer 
cells [2].  
Somatic mutations involving the FLT3 gene include internal tandem duplication 
(ITD) of the juxtamembrane domain or point mutations.  FLT3 mutations that have been 
identified in 7-9% of AML patients appear to activate the tyrosine kinase domain (KD) 
through receptor dimerization in a FLT3 ligand-independent manner [12].  A number of 
studies have shown that FLT3 ITD mutations are of significant clinical consequence and 
4may be associated with disease progression [6] and an increased risk of relapse and shorter 
overall survival [4].   Previous studies have found that FLT3 ITD mutations occur in 
approximately 17-34% of adult AML, 5-17% pediatric AML, 3% in MDS, and 3% in 
pediatric ALL [16].
Two classifications of FLT3 mutations have recently been described, those which 
interfere with the regulatory function of the juxtamembrane region which is seen with 
internal tandem duplication of FLT3 (ITD) and those involving KD point mutations which 
occur within the activation loop (AL) of the second kinase domain [16] (Fig. 2).  
Both mutations constitutively 
activate the receptor’s tyrosine kinase activity in the absence of the ligand.  The FLT3 ITD
have been shown to downregulate a number of important transcription factors, CEBP & 
Pu.1, that are involved in normal myeloid proliferation and differentiation [12].    In ITD 
mutations, FLT3 ITD receptors dimerize in ligand-independent manner, leading to 
autophosphorylation of receptor through constituitive activation of the tyrosine kinase 
domain [12]. FLT3 ITD expression was also shown to suppress radiation-induced apoptosis 
[12].  
5Collaboration between the MLL PTD and FLT3 ITD in leukemogenesis  
In unselected cases of AML, a higher incidence of MLL PTD in FLT3 ITD 
positive patients was significantly higher than in FLT3 ITD negative patients [13].  The 
coexistence of both genetic aberrations may suggest either a common or cooperating 
underlying mechanism of transformation.  To investigate further address this hypothesis
as well as better understand the role of the Mll PTD in generating leukemia, members of 
the Caligiuri Lab developed a mouse ‘knock-in’ model of the Mll PTD.  These mice 
express the Mll PTD transcript as well as the concomitant Mll wildtype (WT) transctipt. 
Although the Caligiuri lab observed aberrant proliferation in the hematopoietic progenitor 
cells (HPCs) in the MllPTD/wt mouse, these mice do not develop leukemia during their 
normal lifespan (>2years) (Table 1). Through colony forming assays (CFU), competitive 
repopulation methods, and assessment via bromodeoxyuridine (BrdU), the lab’s findings 
suggest that the role of Mll PTD is to ready the hematopoietic compartment to be further 
induced into a leukemic phenotype when in the presence of a second hit in differentiation 
and/or apoptosis.  
Recent studies show that FLT3 is overexpressed in AML with MLL translocations.  
In human AML, the MLL PTD has been shown to simultaneously occur with tyrosine 
kinase mutations, such as the FLT3 internal tandem duplication (ITD) [13, 15].  Internal 
tandem duplications (ITD) within the juxtamembrane domain of FLT3 in patients with 
AML occur in approximately 25% (119/523) of patients with normal cytogenetics [4]. 
To further investigate how the FLT3 ITD cooperates with the MLL PTD in leukemic 
transformation, we obtained mice heterogenous for the FLT3 ITD from our collaborators 
at the Gilliland Lab.  Dr. Gilliland’s group has shown that the Flt3ITD/ITD and Flt3ITD/wt
6mice breed normally and live a relatively normal life span.  However, they present with 
enlarged livers, increases in their hemoglobin and platelet counts, splenomegaly, and 
increases in mature monocyte and granulocyte populations.  Furthermore, these knock-in 
mice display a block in B cell development characterized by increases in B220+CD43-
pre-B cells and decreases in the more mature B220+IgM+ cell types.   Flt3ITD/ITD and 
Flt3ITD/wt mice also have increases in the number of hematopoietic progenitor cells (HPCs) 
as quantified by colony forming unit (CFU) assays.  However, unlike the MllPTD/wt
progenitors, these progenitor cells do not display concomitant increases in self-renewal, 
as determined by serial re-plating assays [7]. Two groups who have generated knock-in 
models of FLT3 ITD confirm this observation and although these mice display myeloid-
associated phenotypes, fatal leukemia was not detected over the normal lifespan of these 
mice [7, 9].
Although both Flt3 ITD and Mll PTD mice both display aberrant hematopoietic 
development, a critical step in the leukemogenic pathway, neither develop leukemia over 
their normal lifespan However, Mll PTD mice and Flt3 ITD mice do not acquire acute 
leukemia separately.  These studies support the Knudson’s two-hit hypothesis in that 
these mutations alone are not sufficient to generate leukemia by themselves, and the 
presence of a ‘second-hit’ is needed in order to generate full-blown leukemia.  The 
purpose of this study is to determine if the presence of both the MLL PTD and FLT3 ITD 
mutations are sufficient for leukemogenesis and to use this novel leukemia model to 
investigate novel therapies not only for patients harboring both mutations, but possibly 
patients harboring only one of these mutations. 
7RESULTS
To investigate whether the FLT3 ITD mutation cooperates with the MLL PTD and 
thus providing the “second hit” in for cellular transformation, Flt3ITD/wt and MllPTD/wt
mice were mated to create and characterize the Mll PTD/wt Flt3ITD/wt double mutant mouse 
model. Flt3ITD/wt pups were mated each generation to pure MllPTD/wt -C57Bl/6J mice to 
generate a ‘pure’ Mll PTD/wt Flt3ITD/wt –C57Bl/6J line.  The genotype of the MllPTD/wt
Flt3ITD/wt mice was determined via PCR analysis (Fig. 3).  We have currently backcrossed 
these mice 8 generations.  MllPTD/wt Flt3ITD/wt mice are born at normal Mendalian ratios 
with no signs of delayed growth.  After initial matings, we observed that all of the Mll 
PTD/wt Flt3ITD/wt mice died within 40 weeks of age while none of the littermate controls 
showed any premature death.  Subsequent generations of these mice have lived up to 65 
weeks of age, but still died prematurely below the expected natural lifespan (>104 weeks).  
In fact, no Mll PTD/WT Flt3ITD/WT mice yet to survive past 65 weeks of age (n>15 mice, 
p<0.001).  However, all MllPTD/wt and Flt3ITD/wt littermate controls all live normal life 
spans.  
Mice were monitored weekly for loss of activity and/or weight, but in early litters, 
mice showed no visible signs of disease, making it exceedingly difficult to catch the Mll 
PTD/WT Flt3ITD/WT mice before death. In subsequent litters, the animals were observed 
daily while complete blood counts (CBCs) and weights were taken weekly. Mll PTD/WT
Flt3ITD/WT mice displaying signs of disease (as assessed by CBCs or loss of activity)were 
sacrificed, and tissues were harvested to determine cause of death.  At time of death, 
mice(n=4) presented with anemia and with a greater than 20 fold-increase in WBCs 
compared to littermate controls (Fig. 4).  More importantly, cytospins of the bone
8marrow and spleen, and corresponding blood smears all showed 20-80% of blasts 
present. Furthermore, immuno-histochemistry (IHC) revealed infiltration of leukemic 
blasts in all tissues examined to date (Fig. 5).    
In two of the Mll PTD/WT Flt3ITD/WT mice, the leukemia lineage was determined
using flow cytometry (Fig. 6).  These analyses revealed that both mice were full of 
leukemic blasts by morphology but differed in their immunophenotype.  One mouse, 
identified as PF-59, had a markedly expanded Mac1+/Gr1+ myeloid population (~53%) 
in the spleen, with relatively little CD3 positive T cells or B220 positive B cells. In 
examining PF-59’s tissues, it was evident that there was some limited degree of myeloid 
maturation occurring among the predominance of immature blast forms.  The other 
mouse, identified as PF-72, showed no significant  Mac1+/Gr1+ double positive 
population but rather an increased B220 (dim positive) population and no significant CD3 
T cell population. Unlike mouse PF-59, mouse PF-72’s also showed a significant c-kit 
positive population (~35%).
The immuno-histochemistry results from PF-59 for myeloperoxidase (MPO) 
showed a significant degree of expression in a large proportion of these blasts (Fig. 7).  
Interestingly, there was also a significant subset that appeared positive for Terminal 
Deoxynucleotidyl Transferase (TdT) as well as a subset that appeared to show variable, 
weak B220 expression.  In mouse PF-72, the initial flow results which showed a 
significant B220 positive population were confirmed by IHC for B220 in showing a 
significant staining pattern for B220, with a subset staining positive for TdT, but no CD3 
staining. Interestingly, there was some significant staining for a small proportion of the 
blasts for MPO, which was consistent with the dim Mac1 staining seen initially by flow.
9DISCUSSION
AML is a heterogeneous disease and can result from unique gene fusions as a 
result of chromosomal translocations but can also develop in cells in which no other 
cytogentic alterations are visible (i.e. normal cytogenetics).   Some of these intra-gene 
disruptions can lead to incorrect activation of signal transduction pathways, alterations of 
growth factor receptors, and ultimately disease [10].  Our studies on a double knock-in
mouse model demonstrates that FLT3 ITD can collaborate with the MLL PTD to induce
acute leukemia in an in vivo mouse model.  100% of the Mll PTD/WT Flt3ITD/WT mice 
observed thus far, die between 35-65 weeks of age with massive leukemic infiltration of 
their organs.  Consequently, our studies suggest that cooperation between different 
mutations such as the MLL PTD and mutants leading to constitutive FLT3 activation, 
ensures full transformation of hematopoietic cells and that the combination of these 
mutations are interdependent in the pathogenesis of AML.
As previously mentioned, our Mll PTD/WT Flt3ITD/WT mice were observed to have 
infiltration of disease in the hematopoietic organs.  In fact, up to ~24 hours before death, 
these mice display normal activity, demonstrating the acute nature of the disease.  The 
immunohistochemistry studies revealed that two Mll PTD/WT Flt3ITD/WT mice had acute 
leukemias with biphenotypic features.  In the two cases, Mouse PF-59’s blasts show a 
greater degree of MPO expression while Mouse PF-72’s blasts expressed a greater degree 
of B220 staining pattern.  FLT3 is known to be overexpressed at the RNA and protein 
level in most B lineage and AML [12].  As a result, while Mouse PF-59 appears to 
display a more myeloid-predominant phenotype, Mouse PF-72 appears to display a more 
lymphoid-predominant phenotype.  
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Understanding how the MLL PTD may contribute to leukemogenesis in 
combination with the FLT3 ITD is very important.  With our unique mouse model 
expressing both the Mll PTD and Flt3 ITD, we can begin to assess the contribution of the 
MLL PTD and FLT3 ITD before and after leukemic transformation and positively impact 
AML patients harboring these mutations. Further characterization of this leukemia which 
includes examining altered epigenetic modifications at the promoters of MLL downstream 
target genes may lead to innovative therapeutic approaches.  Furthermore, FLT3 selective 
inhibitors may be used in combination with agents that target disruptions caused by the
MLL PTD.  
Because mutant forms of FLT3 are energetically difficult to fold, they appear
more dependent on chaperone proteins [12]. One way to target mutant FLT3 would be to 
use inhibitors of chaperone proteins like Hsp90 [12].  Another way to inhibit FLT3 would 
be by using anti-FLT3 antibodies to block binding to FL (FLT3 ligand).  Already, some 
FLT3 inhibitors have been tried in clinical trial in relapsed or refractory AML patients, 
where some or all had FLT3 mutations [12].  FLT3 inhibitors can work to suppress FLT3 
tyrosine kinase activity and induce growth arrest/apoptosis in leukemia cells expressing 
FLT3 mutants [16]. However, FLT3 mutations occuring in the setting of acute leukemia
is but one of several somatic genetic alterations required to fully transform cells and may 
need combination therapy to be fully effective. 
Our model will help explore the role of these two leukemogenic mutations in the 
development of AML and we hope to identify new aberrant pathways that may 
subsequently lead to novel targeted therapies and new treatments for AML patients with
these mutations.  
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MATERIALS AND METHODS
Mice and genotype analysis
Mice heterozygous for the FLT3 ITD were obtained from our collaborator, Dr. D. 
Gary Gilliland at Harvard University. Mice harboring the FLT3 ITD at the endogenous 
FLT3 locus were maintained on an FVB background.  Mice heterozygous for MLL PTD 
were maintained on a pure C57B1/6J background and were crossed with the FLT3WT/ITD
mice.  In each generation FLT3WT/ITD offspring were bred to pure MllPTD/WT- C57Bl/6J to 
generate the MllPTD/WT FLT3WT/ITD double mutants on a pure C57Bl/6J background.  
Genotyping was performed via PCR analysis.  DNA samples from the tail were prepped 
using the Qiagen DNeasy DNA extraction kit.  Both the FLT3ITD/WT and the wildtype 
FLT3WT/WT alleles were detected at ~200 bp and ~220 bp respectively using the following 
primers Flt314F (5’-AGG TAC GAG AGT CAG CTG CAG ATG-3’) and Flt314R (5’-
TGT AAA GAT GGA GTA AGT GCG GGT-3’) and the following parameters: 95ºC for 
2 min, followed by 35 cycles of  95ºC for 1 min, 60ºC for 1 min, and 72ºC for 50s (see 
fig. 3).  The MllPTD/WT mice were genotyped by PCR with primers 642F (5’–GAG CCT
TGG CCC GAA TGA AAC TGT-3’) and 643R (5’-CCG GCG AAC GTG GCG AGA
AA-3’), and the PTD mutant allele was detected at ~900 bp using the following 
parameters: 95ºC for 2 min, followed by 35 cycles of 95ºC for 30s, 66ºC for 30s, and 
72ºC for 2 min, and 72ºC for 10 min.   
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Complete Blood Count (CBC) test
Mice starting at 16 weeks of age were bled weekly using submandibular bleeding 
methods.  Collected blood samples were submitted to the Veterinary Teaching Hospital at 
The Ohio State University, and the reported white blood counts (WBCs) were compared 
to littermate controls, weekly to monitor the progression of disease in the mice.  
Histopathology
Harvested tissues at the time of death were fixed for histological examination in 
10% formalin and sent to Goss Labs and the Veterinary Teaching Hospital at The Ohio 
State University.    
Peripheral blood smears and bone marrow and spleen cytospins were prepared 
with Wright-Giemsa staining for morphologic evaluation.  
Flow Cytometry
For multiparameter flow cytometry, bone marrow , spleen, and peripheral blood
cells from Mll PTD/WT Flt3ITD/WT mice PF-59 and PF-72 were analyzed via standard 
protocols for flow cytometry using antibodies Gr1, Mac1, c-Kit, B220, and CD3.
Immunofluorescent analysis of antigen expression was performed as previously described 
[7, 8]
Immunohistochemistry (IHC)
Immunohistochemistry was performed on Mll PTD/WT Flt3ITD/WT mice, PF-59 and 
PF-72, cell blasts via standard protocols using primary antibodies to B220 (PharMingen), 
myeloperoxidase (MPO; Dako), Terminal Deoxynucleotidyl Transferase (TdT), CD3 
(Dako), and Mac1 (AbCam) [7, 8].
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Fig. 3 PCR Analysis of MllPTD/wt and Flt3ITD/wt  A.) Sequence of PCR product 
for MllPTD/wt. The 1 kb+ ladder was used to determine amplification size. B.) 
Sequence of PCR product for Flt3 ITD/wt. 
FIGURES AND TABLES
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Fig. 4 WBCs at time of death.
WBCs at time of death show a greater than 20 fold increase in the number of 
WBCs in the MllPTD/wt Flt3ITD/wt  mice compared to littermate controls.
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Fig. 5  Extensive infiltration of MllPTD/wt Flt3ITD/wt leukemic cells. A.) BM 
shown here at 40X demonstrates how the disease cells have completely 
infiltrated and taken over the BM space. B.) The adrenal gland shown here at 4X 
demonstrates large masses of diseased cells. 
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Fig. 6 Lineage determination of two Mll PTD/WT Flt3ITD/WT mice who 
succumbed to leukemia. Mouse PF-59 (left) developed AML (Gr1+ Mac1+
Kit/dim B220-CD3-) while mouse PF-72 (right) developed acute undifferentiated 
leukemia (Gr1-Mac1-Kit+B220dimCD3-). Admixed among the blast population are 
a smaller population of more mature myeloid forms (yellow arrows), indicating 
that there is some limited myeloid maturation occurring.
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Fig. 7  Immunohistochemistry analysis of two Mll PTD/WT Flt3ITD/WT mice 
who developed leukemia. A.) Spleen cells of mouse PF-59 (left) and PF-72 
(right). B.) Mouse PF-59 shows a lot more cells stained with MPO or with 
Mac1+/Gr1+ expression than PF-72. C.) Both mice show significant staining 
for TdT. D.) Mouse PF-72 shows significantly more staining for B220 
expression. E.) Both mice show no CD3 expression. 
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